Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes

Immunology and Microbiology

• T Cell 100%
• T-Helper Cell 100%
• Erythropoietin 100%
• CD4 80%
• Cytotoxic T-Cell 80%
• Epoetin Beta 60%
• CD25 40%
• Normal Human 20%
• Phytohaemagglutinin 20%
• CD8 20%
• CD69 20%
• Cell Count 20%
• CD28 20%
• CD8+ Cell 20%
• Immune System 20%

Keyphrases

• Myelodysplastic Syndrome 100%
• T Cells 100%
• Erythropoietin 100%
• Cell Properties 100%
• CD4+ 33%
• CD8+ T Cells 22%
• RhEPO 16%
• CD4+CD25+ 11%
• Disease Severity 5%
• Immune System 5%
• Subgroup Analysis 5%
• CD4+ T Cells 5%
• Cell number 5%
• Fold Increase 5%
• Advanced Disease 5%
• In Vitro Activation 5%
• CD8+ 5%
• Erythropoietin Therapy 5%
• Co-stimulatory Markers 5%
• CD8+ Cells 5%
• Phytohemagglutinin 5%
• CD69 Expression 5%
• Immune Abnormalities 5%
• Mild Disease 5%
• CD28 5%